Quest for the right Drug
אוטרוגסטן 200 UTROGESTAN 200 (PROGESTERONE MICRONIZED)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
וגינלי, פומי : VAGINAL, PER OS
צורת מינון:
קפסולות : CAPSULES
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
4.8. Undesirable effects: Oral administration: The following effects have been seen: Common Uncommon Rare Very rare System organ undesirable undesirable undesirable undesirable class effects ≥1/100; effects ≥1/1000; effects ≥1/10 effects ≤1/10 <1/10 ≤1/100 000; ≤1/1 000 000 -Altered -Mastodynia Reproductive periods system and breast -Amenorrhoea disorders -Intercurrent bleeding -Headaches -Drowsiness -Depression Central nervous -Fleeting dizzy system disorders sensations -Vomiting -Nausea Gastrointestinal -Diarrhoea disorders -Constipation Hepatobiliary -Cholestatic disorders jaundice Immune system -Urticaria disorders Skin and -Pruritus -Chloasma subcutaneous -Acne tissue disorders Drowsiness and/or fleeting dizzy sensations are seen particularly with concomitant hypoestrogenism. These effects disappear immediately without compromising the benefit of treatment when doses are reduced or oestrogenism is increased. If the treatment sequence is started too early in the month, particularly before the 15th day of the cycle, the cycle may be shortened or intercurrent bleeding may occur. Changes in periods, amenorrhoea or intercurrent bleeding have been observed and associated with the use of progesterones in general. Vaginal administration Despite the possibility of local irritation may occur (soya lecithin), no significant local intolerance (burning, pruritus or greasy discharge) has been observed during different clinical trials. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form: https://sideeffects.health.gov.il/
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
01/04/2004
הגבלות
תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת
מידע נוסף